Crescent Biopharma, Inc.
CBIO
$10.60
$0.252.42%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 31.98% | -38.12% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 295.35% | 23.09% | |||
| Operating Income | -253.46% | -23.09% | |||
| Income Before Tax | -267.36% | -12.93% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -275.49% | -12.93% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -275.49% | -12.93% | |||
| EBIT | -253.46% | -23.09% | |||
| EBITDA | -253.63% | -22.96% | |||
| EPS Basic | -216.39% | 74.30% | |||
| Normalized Basic EPS | -209.54% | 74.30% | |||
| EPS Diluted | -216.39% | 74.30% | |||
| Normalized Diluted EPS | -209.54% | 74.30% | |||
| Average Basic Shares Outstanding | 18.68% | 339.37% | |||
| Average Diluted Shares Outstanding | 18.68% | 339.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||